The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.
 
Efrat Dotan
Consulting or Advisory Role - Basilea Pharmaceutical; Helsinn Therapeutics; Incyte; QED Therapeutics
Research Funding - AstraZeneca (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Zymeworks (Inst)
 
Paul J. Catalano
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Regeneron (Inst)
 
Leon Lenchik
No Relationships to Disclose
 
Robert Boutin
No Relationships to Disclose
 
Xin Yao
Honoraria - Research to Practice; Xcenda
 
Shaalan Shaalan Beg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Cancer Commons; Foundation Medicine; Ipsen; Legend Biotech
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmuneSensor Therapeutics (Inst); MedImmune (Inst); Merck Serono (Inst); Tolero Pharmaceuticals (Inst)
 
Namrata Vijayvergia
Stock and Other Ownership Interests - Pfizer (I)
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; AstraZeneca/Daiichi Sankyo; HalioDx; Isotopen Technologien; Lexicon; Novartis; QED Therapeutics; Sun Pharma; Taiho Oncology; Tersera
Research Funding - Zymeworks
 
Constantine Gatsonis
No Relationships to Disclose
 
David Bing Zhen
Consulting or Advisory Role - QED Therapeutics
Research Funding - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Seagen
 
Daneng Li
Consulting or Advisory Role - Adagene; Advanced Accelerator Applications; Eisai; Exelixis; Genentech; Ipsen; Lexicon; Merck; MINA THERAPEUTICS; QED Therapeutics; Taiho Pharmaceutical; Tersera
Speakers' Bureau - Advanced Accelerator Applications; Coherus Biosciences; Eisai; Exelixis; Ipsen; Lexicon; Sun Pharma; Tersera
Research Funding - AstraZeneca (Inst); Brooklyn ImmunoTherapeutics (Inst)
 
Lynne I. Wagner
Stock and Other Ownership Interests - Gilead Sciences (I); Johnson & Johnson (I); Lilly (I)
Consulting or Advisory Role - Athenex; Celgene
Travel, Accommodations, Expenses - Celgene
 
Melissa A. Simon
No Relationships to Disclose
 
Terence Z. Wong
Consulting or Advisory Role - GE Healthcare
Research Funding - Blue Earth Diagnostics (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
Peter J. O'Dwyer
Consulting or Advisory Role - Genentech
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Dai-ichi Sankyo; Lilly